Ellipses in-licenses first-in-class B7H3 Antibody Drug Conjugate from China

CAR-T Digest - August 2020

Weekly Digest - January 2026

19 January 2026: Ellipses in-licenses first-in-class B7H3 Antibody Drug Conjugate from China

Ellipses Pharma announced that it has entered into a collaboration and licensing agreement with Innolake Biopharm to in-license a first-in-class B7H3-targeted antibody-drug conjugate, strengthening its clinical-stage oncology pipeline with a differentiated ADC program originating from China
Under the agreement, Ellipses acquires global development rights outside greater China to ILB-3101, an eribulin-payload ADC with the potential to treat multiple tumor types and address resistance seen with topoisomerase I–based ADCs, which will be developed under the Ellipses code EP0028
The two companies will work closely on advancing EP0028, which is currently being evaluated in a Phase 1 clinical trial in China sponsored by Innolake, while Ellipses plans to initiate a separate Phase 1 study in the United States, with subsequent expansion into Europe and other regions following regulatory approvals
This transaction marks the second oncology program Ellipses has in-licensed from an innovative Chinese biotech, following EP0031, a next-generation RET inhibitor from Kelun Biotech that is already progressing through Phase 2 development, reinforcing Ellipses’ strategy of translating high-quality Chinese innovation for Western markets
Company leadership highlighted the deal as both a validation of Innolake’s technology and a strategic step for Ellipses in building a pipeline focused on high-unmet-need cancers, with the partnership aimed at rapidly advancing EP0028 toward global clinical impact